Other
CN
EU
USA
Description: Birinapant (TL32711; TL-32711; TL 32711) is a novel and potent bivalent SMAC peptido-mimetic antagonist, mostly to cIAP1 with Kd of<1 nM in a cell-free assay, less potent to XIAP. Birinapant not only binds to the isolated BIR3 domains of cIAP1, cIAP2, XIAP but the single BIR domain of ML-IAP with high affinity and degrades TRAF2-bound cIAP1 and cIAP2 rapidly accordingly inhibiting the activation of TNF-mediated NF- kB. Additionally, birinapantcan promote the formation of caspase-8: RIPK1 complex in response to TNF stimulation, which result in downstream caspasesactivation.
References: Breast Cancer Res Treat. 2013 Jan;137(2):359-71.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
Lot#: V005101,Purity ≥98%
COA
MSDS
NMR